Microtubule stabilizing agents as potential treatment for alzheimers disease and related neurodegenerative tauopathies

Journal of Medicinal Chemistry

Volumn 55, Issue 21, 2012, Pages 8979-8996

  Ballatore, Carlo ^a,b   Brunden, Kurt R ^b   Huryn, Donna M ^a   Trojanowski, John Q ^b   Lee, Virginia M Y ^b   Smith, Amos B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERATAMINE DERIVATIVE; CYCLOSTREPTIN; DAVUNETIDE; DICOUMAROL; DICTYOSTATIN; DISCODERMOLIDE; ELEUTHESIDE DERIVATIVE; EPOTHILONE DERIVATIVE; JATROPHANE DERIVATIVE; LAULIMALIDE; MICROTUBULE STABILIZING AGENT; NATURAL PRODUCT; PELORUSIDE; TACCALONOLIDE DERIVATIVE; TAU PROTEIN; TAXANE DERIVATIVE; TUBERCIDIN; UNCLASSIFIED DRUG; XANTHOPHYLL; ZAMPANOLIDE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; IN VITRO STUDY; IN VIVO STUDY; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; AXONAL TRANSPORT; BIOLOGICAL AGENTS; BLOOD-BRAIN BARRIER; HUMANS; MICROTUBULES; MOLECULAR TARGETED THERAPY; TAU PROTEINS; TAUOPATHIES;

EID: 84868514765     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301079z     Document Type: Review

References (237)

1. Desai, A.; Mitchison, T. J. Microtubule polymerization dynamics Annu. Rev. Cell Dev. Biol. 1997, 13, 83-117
2. Mitchison, T.; Kirschner, M. Dynamic instability of microtubule growth Nature 1984, 312, 237-242
3. Roy, S.; Zhang, B.; Lee, V. M.-Y.; Trojanowski, J. Q. Axonal transport defects: a common theme in neurodegenerative diseases Acta Neuropathol. 2005, 109, 5-13
4. De Vos, K. J.; Grierson, A. J.; Ackerley, S.; Miller, C. C. Role of axonal transport in neurodegenerative diseases Annu. Rev. Neurosci. 2008, 31, 151-173
5. Lee, V. M.-Y.; Goedert, M.; Trojanowski, J. Q. Neurodegenerative tauopathies Annu. Rev. Neurosci. 2001, 24, 1121-1159
6. Drechsel, D. N.; Hyman, A. A.; Cobb, M. H.; Kirschner, M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau Mol. Biol. Cell 1992, 3, 1141-1154
7. Biernat, J.; Gustke, N.; Drewes, G.; Mandelkow, E. M.; Mandelkow, E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding Neuron 1993, 11, 153-163
8. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Rev. 2000, 33, 95-130
9. Kuret, J.; Congdon, E. E.; Li, G.; Yin, H.; Yu, X.; Zhong, Q. Evaluating triggers and enhancers of tau fibrillization Microsc. Res. Tech. 2005, 67, 141-155
10. Kuret, J.; Chirita, C. N.; Congdon, E. E.; Kannanayakal, T.; Li, G.; Necula, M.; Yin, H.; Zhong, Q. Pathways of tau fibrillization Biochim. Biophys. Acta, Mol. Basis Dis. 2005, 1739, 167-178
11. Ballatore, C.; Lee, V. M.-Y.; Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimers disease and related disorders Nat. Rev. Neurosci. 2007, 8, 663-672
12. Hempen, B.; Brion, J. P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimers disease J. Neuropathol. Exp. Neurol. 1996, 55, 964-972
13. Lee, V. M.-Y.; Daughenbaugh, R.; Trojanowski, J. Q. Microtubule stabilizing drugs for the treatment of Alzheimers disease Neurobiol. Aging 1994, 15 (Suppl. 2) S87-S89
14. Trojanowski, J. Q.; Smith, A. B.; Huryn, D.; Lee, V. M.-Y. Microtubule-stabilizing drugs for therapy of Alzheimers disease and other neurodegenerative disorders with axonal transport impairments Expert Opin. Pharmacother. 2005, 6, 683-686
15. Tsuji, A.; Tamai, I. Bloo-brain barrier function of P-glycoprotein Adv. Drug Delivery Rev. 1997, 25, 287-298
16. Pardridge, W. M. The bloo-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2, 3-14
17. Pardridge, W. M. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discovery Today 2002, 7, 5-7
18. Bedard, P. L.; Di Leo, A.; Piccart-Gebhart, M. J. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer Nat. Rev. Clin. Oncol. 2010, 7, 22-36
19. Lee, J.; Swain, S. M. Peripheral neuropathy induced by microtubule-stabilizing agents J. Clin. Oncol. 2006, 24, 1633-1642
20. Shemesh, O. A.; Spira, M. E. Rescue of neurons from undergoing hallmark tau-induced Alzheimers disease cell pathologies by the antimitotic drug paclitaxel Neurobiol. Dis. 2011, 43, 163-175
21. Das, V.; Miller, J. H. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation Eur. J. Neurosci. 2012, 35, 1705-1717
22. Michaelis, M. L.; Ranciat, N.; Chen, Y.; Bechtel, M.; Ragan, R.; Hepperle, M.; Liu, Y.; Georg, G. Protection against beta-amyloid toxicity in primary neurons by paclitaxel (Taxol) J. Neurochem. 1998, 70, 1623-1627
23. Michaelis, M. L.; Chen, Y.; Hill, S.; Reiff, E.; Georg, G.; Rice, A.; Audus, K. Amyloid peptide toxicity and microtubule-stabilizing drugs J. Mol. Neurosci. 2002, 19, 101-105
24. Michaelis, M. L.; Ansar, S.; Chen, Y.; Reiff, E. R.; Seyb, K. I.; Himes, R. H.; Audus, K. L.; Georg, G. I. {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents J. Pharmacol. Exp. Ther. 2005, 312, 659-68
25. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E. B.; Xie, S. X.; Joyce, S.; Li, C.; Toleikis, P. M.; Lee, V. M.-Y.; Trojanowski, J. Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 227-231
26. Brunden, K. R.; Zhang, B.; Carroll, J.; Yao, Y.; Potuzak, J. S.; Hogan, A. M.; Iba, M.; James, M. J.; Xie, S. X.; Ballatore, C.; Smith, A. B.; Lee, V. M.; Trojanowski, J. Q. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy J. Neurosci. 2010, 30, 13861-13866
27. Zhang, B.; Carroll, J.; Trojanowski, J. Q.; Yao, Y.; Iba, M.; Potuzak, J. S.; Hogan, A. M.; Xie, S. X.; Ballatore, C.; Smith, A. B.; Lee, V. M.; Brunden, K. R. The microtubule-stabilizing agent, epothilone d, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice J. Neurosci. 2012, 32, 3601-3611
28. Barten, D. M.; Fanara, P.; Andorfer, C.; Hoque, N.; Wong, P. Y. A.; Husted, K. H.; Cadelina, G. W.; DeCarr, L. B.; Yang, L.; Liu, L.; Fessler, C.; Protassio, J.; Riff, T.; Turner, H.; Janus, C. G.; Sankaranarayanan, S.; Polson, C.; Meredith, J. E.; Gray, G.; Hanna, A.; Olson, R. E.; Kim, S.-H.; Vite, G. D.; Lee, F. Y.; Albright, C. F. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027 J. Neurosci. 2012, 32, 7137-7145
29. Yoshiyama, Y.; Higuchi, M.; Zhang, B.; Huang, S.-M.; Iwata, N.; Saido, T. C.; Maeda, J.; Suhara, T.; Trojanowski, J. Q.; Lee, V. M. Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model Neuron 2007, 53, 337-351
30. Study To Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease. http://clinicaltrials.gov/ct2/show/NCT01492374?term=BMS-241027&rank=1.
31. Irwin, D. J.; White, M. T.; Toledo, J. B.; Xie, S. X.; Robinson, J. L.; Van Deerlin, V.; Lee, V. M.-Y.; Leverenz, J. B.; Montine, T. J.; Duda, J. E.; Hurtig, H. I.; Trojanowski, J. Q. Neuropathologic substrates of Parkinsons disease dementia. Ann. Neurol. [Online early access]. DOI: 10.1002/ana.23659. Published Online: Jun 13, 2012.
32. Galsky, M. D.; Dritselis, A.; Kirkpatrick, P.; Oh, W. K. Cabazitaxel Nat. Rev. Drug Discovery 2010, 9, 677-678
33. Laccabue, D.; Tortoreto, M.; Veneroni, S.; Perego, P.; Scanziani, E.; Zucchetti, M.; Zaffaroni, M.; DIncalci, M.; Bombardelli, E.; Zunino, F.; Pratesi, G. A novel taxane active against an orthotopically growing human glioma xenograft Cancer 2001, 92, 3085-3092
34. Rice, A.; Liu, Y.; Michaelis, M. L.; Himes, R. H.; Georg, G. I.; Audus, K. L. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the bloo-brain barrier in vitro and in situ J. Med. Chem. 2005, 48, 832-838
35. Régina, A.; Demeule, M.; Ché, C.; Lavallée, I.; Poirier, J.; Gabathuler, R.; Béliveau, R.; Castaigne, J. P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2 Br. J. Pharmacol. 2008, 155, 185-197
36. Brunden, K. R.; Yao, Y.; Potuzak, J. S.; Ferrer, N. I.; Ballatore, C.; James, M. J.; Hogan, A. M.; Trojanowski, J. Q.; Smith, A. B.; Lee, V. M. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimers disease and related tauopathies Pharmacol. Res. 2011, 63, 341-351
37. Hoffmann, J.; Fichtner, I.; Lemm, M.; Lienau, P.; Hess-Stumpp, H.; Rotgeri, A.; Hofmann, B.; Klar, U. Sagopilone crosses the bloo-brain barrier in vivo to inhibit brain tumor growth and metastases Neuro-Oncology 2009, 11, 158-166
38. OReilly, T.; Wartmann, M.; Brueggen, J.; Allegrini, P. R.; Floersheimer, A.; Maira, M.; McSheehy, P. M. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo Cancer Chemother. Pharmacol 2008, 62, 1045-1054
39. Wall, M. E.; Wani, M. C. Presented at the 153rd National Meeting of the American Chemical Society, Miami Beach, FL, 1967; Paper M-006.
40. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J. Am. Chem. Soc. 1971, 93, 2325-2327
41. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol Nature 1979, 277, 665-667
42. Nogales, E.; Wolf, S. G.; Khan, I. A.; Luduena, R. F.; Downing, K. H. Structure of tubulin at 6.5 Å and location of the Taxol-binding site Nature 1995, 375, 424-427
43. Díaz, J. F.; Barasoain, I.; Andreu, J. M. Fast kinetics of taxol binding to microtubules J. Biol. Chem. 2003, 278, 8407 - 8419
44. Barasoain, I.; García-Carril, A. M.; Matesanz, R.; Maccari, G.; Trigili, C.; Mori, M.; Shi, J.-Z.; Fang, W.-S.; Andreu, J. M.; Botta, M.; Díaz, J. F. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses Chem. Biol. 2010, 17, 243-253
45. Amos, L. A. Microtubule structure and its stabilisation Org. Biomol. Chem. 2004, 2, 2153-2160
46. Samsonov, A.; Yu, J. Z.; Rasenick, M.; Popov, S. V. Tau interaction with microtubules in vivo J. Cell Sci. 2004, 117, 6129-6141
47. Amos, L. A.; Lowe, J. How Taxol stabilises microtubule structure Chem. Biol. 1999, 6, R65-R659
48. Eisenhauer, E. A.; Vermorken, J. B. The taxoids: comparative clinical pharmacology and therapeutic potential Drugs 1998, 55, 5-30
49. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265
50. Denis, J. N.; Greene, A. E.; Guenard, D.; Gueritte-Voegelein, F.; Mangatal, L.; Potier, P. Highly efficient, practical approach to natural Taxol J. Am. Chem. Soc. 1988, 110, 5917-5919
51. Guenard, D.; Gueritte-Voegelein, F.; Potier, P. Taxol and taxotere: discovery, chemistry, and structure-activity relationships Acc. Chem. Res. 1993, 26, 160-167
52. Kingston, D. G.; Jagtap, P. G.; Yuan, H.; Samala, L. The chemistry of Taxol and related taxoids Fortschr. Chem. Org. Naturst. 2002, 84, 53-225
53. Ojima, I. Recent advances in the.beta.-lactam synthon method Acc. Chem. Res. 1995, 28, 383-389
54. Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C. M.; Brigaud, T. New and efficient approaches to the semisynthesis of Taxol and its C-13 side chain analogs by means of β-lactam synthon method Tetrahedron 1992, 48, 6985-7012
55. Georg, G. I.; Cheruvallath, Z. S.; Himes, R. H.; Mejillano, M. R.; Burke, C. T. Synthesis of biologically active Taxol analogs with modified phenylisoserine side chains J. Med. Chem. 1992, 35, 4230-4237
56. Holton, R. A. Method for Preparation of Taxol Using beta Lactam. US005175315A, 1992.
57. Expósito, O.; Bonfill, M.; Moyano, E.; Onrubia, M.; Mirjalili, M. H.; Cusidó, R. M.; Palazón, J. Biotechnological production of Taxol and related taxoids: current state and prospects Anti-Cancer Agents Med. Chem. 2009, 9, 109-121
58. Kemper, E. M.; van Zandbergen, A. E.; Cleypool, C.; Mos, H. A.; Boogerd, W.; Beijnen, J. H.; van Tellingen, O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein Clin. Cancer Res. 2003, 9, 2849-2855
59. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhanel, M.; Spruss, T.; Bernhardt, G.; Graeff, C.; Farber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) across the bloo-brain barrier in vitro and in vivo J. Clin. Invest. 2002, 110, 1309-1318
60. Beaulieu, E.; Demeule, M.; Ghitescu, L.; Beliveau, R. P-Glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain Biochem. J. 1997, 326 (Part 2) 539-544
61. Bouchet, B. P.; Galmarini, C. M. Cabazitaxel, a new taxane with favorable properties Drugs Today 2010, 46, 735-742
62. Ferlini, C.; Distefano, M.; Pignatelli, F.; Lin, S.; Riva, A.; Bombardelli, E.; Mancuso, S.; Ojima, I.; Scambia, G. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors Br. J. Cancer 2000, 83, 1762-1768
63. Vredenburg, M. R.; Ojima, I.; Veith, J.; Pera, P.; Kee, K.; Cabral, F.; Sharma, A.; Kanter, P.; Greco, W. R.; Bernacki, R. J. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance J. Natl. Cancer Inst. 2001, 93, 1234-1245
64. Minderman, H.; Brooks, T. A.; OLoughlin, K. L.; Ojima, I.; Bernacki, R. J.; Baer, M. R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 Cancer Chemother. Pharmacol. 2004, 53, 363-369
65. Ojima, I.; Slater, J. C.; Michaud, E.; Kuduk, S. D.; Bounaud, P. Y.; Vrignaud, P.; Bissery, M. C.; Veith, J. M.; Pera, P.; Bernacki, R. J. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells J. Med. Chem. 1996, 39, 3889-3896
66. Ojima, I.; Chen, J.; Sun, L.; Borella, C. P.; Wang, T.; Miller, M. L.; Lin, S.; Geng, X.; Kuznetsova, L.; Qu, C.; Gallager, D.; Zhao, X.; Zanardi, I.; Xia, S.; Horwitz, S. B.; Mallen-St Clair, J.; Guerriero, J. L.; Bar-Sagi, D.; Veith, J. M.; Pera, P.; Bernacki, R. J. Design, synthesis, and biological evaluation of new-generation taxoids J. Med. Chem. 2008, 51, 3203-3221
67. Distefano, M.; Scambia, G.; Ferlini, C.; Gaggini, C.; De Vincenzo, R.; Riva, A.; Bombardelli, E.; Ojima, I.; Fattorossi, A.; Panici, P. B.; Mancuso, S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10- deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells Int. J. Cancer 1997, 72, 844-850
68. Rice, A.; Michaelis, M.; Georg, G.; Liu, Y.; Turunen, B.; Audus, K. Overcoming the bloo-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors J. Mol. Neurosci. 2003, 20, 339-343
69. Mastalerz, H.; Cook, D.; Fairchild, C. R.; Hansel, S.; Johnson, W.; Kadow, J. F.; Long, B. H.; Rose, W. C.; Tarrant, J.; Wu, M. J.; Xue, M. Q.; Zhang, G.; Zoeckler, M.; Vyas, D. M. The discovery of BMS-275183: an orally efficacious novel taxane Bioorg. Med. Chem. 2003, 11, 4315-4323
70. Rose, W. C.; Long, B. H.; Fairchild, C. R.; Lee, F. Y.; Kadow, J. F. Preclinical pharmacology of BMS-275183, an orally active taxane Clin. Cancer Res. 2001, 7, 2016-2021
71. Sampath, D.; Discafani, C. M.; Loganzo, F.; Beyer, C.; Liu, H.; Tan, X.; Musto, S.; Annable, T.; Gallagher, P.; Rios, C.; Greenberger, L. M. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo Mol. Cancer Ther. 2003, 2, 873-884
72. Lockhart, A. C.; Bukowski, R.; Rothenberg, M. L.; Wang, K. K.; Cooper, W.; Grover, J.; Appleman, L.; Mayer, P. R.; Shapiro, M.; Zhu, A. X. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors Cancer Chemother. Pharmacol. 2007, 60, 203-209
73. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain J. Pharmacol. Exp. Ther. 2008, 324, 1064-1072
74. Kurzrock, R.; Gabrail, N.; Chandhasin, C.; Moulder, S.; Smith, C.; Brenner, A.; Sankhala, K.; Mita, A.; Elian, K.; Bouchard, D.; Sarantopoulos, J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors Mol. Cancer Ther. 2012, 11, 308-316
75. Hofle, G.; Reichenbach, H. Epothilone, a Myxobacterial Metabolite with Promising Antitumor Activity. In Anticancer Agents from Natural Products; Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds.; CRC Press: Boca Raton, FL, 2005; pp 413-450.
76. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action Cancer Res. 1995, 55, 2325-2333
77. Ojima, I.; Chakravarty, S.; Inoue, T.; Lin, S.; He, L.; Horwitz, S. B.; Kuduk, S. D.; Danishefsky, S. J. A common pharmacophore for cytotoxic natural products that stabilize microtubules Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4256-4261
78. Reese, M.; Sánchez-Pedregal, V. M.; Kubicek, K.; Meiler, J.; Blommers, M. J. J.; Griesinger, C.; Carlomagno, T. Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution Angew. Chem. 2007, 119, 1896-1900
79. Forli, S.; Manetti, F.; Altmann, K. H.; Botta, M. Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilones ChemMedChem 2010, 5, 35-40
80. Nettles, J. H.; Li, H.; Cornett, B.; Krahn, J. M.; Snyder, J. P.; Downing, K. H. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography Science 2004, 305, 866-869
81. Giannakakou, P.; Sackett, D. L.; Kang, Y. K.; Zhan, Z.; Buters, J. T.; Fojo, T.; Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization J. Biol. Chem. 1997, 272, 17118-17125
82. Hardt, I. H.; Steinmetz, H.; Gerth, K.; Sasse, F.; Reichenbach, H.; Höfle, G. New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies J. Nat. Prod. 2001, 64, 847-856
83. Kolman, A. Epothilone D (Kosan/Roche) Curr. Opin. Invest. Drugs 2004, 5, 657-667
84. Beer, T. M.; Higano, C. S.; Saleh, M.; Dreicer, R.; Hudes, G.; Picus, J.; Rarick, M.; Fehrenbacher, L.; Hannah, A. L. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel Invest. New Drugs 2007, 25, 565-570
85. Lichtner, R. M.; Rotgeri, A.; Klar, U.; Hoffmann, J.; Buchmann, B.; Schwede, W.; Skuballa, W. The Use of Epothilones in the Treatment of Brain Diseases Associated with Proliferative Process. WO 03/074053 A1, 2003.
86. Andrieux, A.; Salin, P.; Schweitzer, A.; Begou, M.; Pachoud, B.; Brun, P.; Gory-Faure, S.; Kujala, P.; Suaud-Chagny, M. F.; Hofle, G.; Job, D. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia Biol. Psychiatry 2006, 60, 1224-1230
87. Lee, C. B.; Wu, Z.; Zhang, F.; Chappell, M. D.; Stachel, S. J.; Chou, T. C.; Guan, Y.; Danishefsky, S. J. Insights into long-range structural effects on the stereochemistry of aldol condensations: a practical total synthesis of desoxyepothilone F J. Am. Chem. Soc. 2001, 123, 5249-5259
88. Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Cho, Y. S.; Chou, T. C.; Dong, H.; Danishefsky, S. J. Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13- desoxyepothilone B as a promising anticancer drug candidate J. Am. Chem. Soc. 2004, 126, 10913-10922
89. Laferriere, N.; MacRae, T.; Brown, D. Tubulin synthesis and assembly in differentiating neurons Biochem. Cell Biol. 1997, 75, 103-117
90. Black, M.; Baas, P.; Humphries, S. Dynamics of alpha-tubulin deacetylation in intact neurons J. Neurosci. 1989, 9, 358-368
91. Balog, A.; Meng, D.; Kamenecka, T.; Bertinato, P.; Su, D.-S.; Sorensen, E. J.; Danishefsky, S. J. Total synthesis of (-)-epothilone A Angew. Chem., Int. Ed. Engl. 1996, 35, 2801-2803
92. Yang, Z.; He, Y.; Vourloumis, D.; Vallberg, H.; Nicolaou, K. C. Total synthesis of epothilone A: the olefin metathesis approach Angew. Chem., Int. Ed. Engl. 1997, 36, 166-168
93. Schinzer, D.; Limberg, A.; Bauer, A.; Böhm, O. M.; Cordes, M. Total synthesis of (-)-epothilone A Angew. Chem., Int. Ed. Engl. 1997, 36, 523-524
94. Altmann, K.-H.; Hofle, G.; Muller, R.; Mulzer, J. H.; Prantz, K.; Kinghorn, A. D., Eds. Epothilones: An Outstanding Family of Anti-Tumor Agents. Springer: New York, 2009.
95. Conlin, A.; Fornier, M.; Hudis, C.; Kar, S.; Kirkpatrick, P. Ixabepilone Nat. Rev. Drug Discovery 2007, 6, 953-954
96. Klar, U.; Buchmann, B.; Schwede, W.; Skuballa, W.; Hoffmann, J.; Lichtner, R. B. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development Angew. Chem., Int. Ed. 2006, 45, 7942-7948
97. Klar, U.; Hoffmann, J.; Giurescu, M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate Expert Opin. Invest. Drugs 2008, 17, 1735-1748
98. Gunasekera, S. P.; Gunasekera, M.; Longley, R. E.; Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta J. Org. Chem. 1990, 55, 4912-4915
99. Longley, R. E.; Caddigan, D.; Harmody, D.; Gunasekera, M.; Gunasekera, S. P. Discodermolide-a new, marine-derived immunosuppressive compound. I. In vitro studies Transplantation 1991, 52, 650-656
100. Longley, R. E.; Caddigan, D.; Harmody, D.; Gunasekera, M.; Gunasekera, S. P. Discodermolide-a new, marine-derived immunosuppressive compound. II. In vivo studies Transplantation 1991, 52, 656-661
101. ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol Biochemistry 1996, 35, 243-250
102. Hung, D. T.; Chen, J.; Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks Taxol binding and results in mitotic arrest Chem. Biol. 1996, 3, 287-293
103. Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells Mol. Pharmacol. 1997, 52, 613-622
104. Xia, S.; Kenesky, C. S.; Rucker, P. V.; Smith, A. B.; Orr, G. A.; Horwitz, S. B. A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin Biochemistry 2006, 45, 11762-11775
105. Martello, L. A.; LaMarche, M. J.; He, L.; Beauchamp, T. J.; Smith, A. B., 3rd; Horwitz, S. B. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies Chem. Biol. 2001, 8, 843-855
106. Khrapunovich-Baine, M.; Menon, V.; Verdier-Pinard, P.; Smith, A. B.; Angeletti, R. H.; Fiser, A.; Horwitz, S. B.; Xiao, H. Distinct pose of discodermolide in Taxol binding pocket drives a complementary mode of microtubule stabilization Biochemistry 2009, 48, 11664-11677
107. Honore, S.; Kamath, K.; Braguer, D.; Horwitz, S. B.; Wilson, L.; Briand, C.; Jordan, M. A. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells Cancer Res. 2004, 64, 4957-4964
108. Martello, L. A.; McDaid, H. M.; Regl, D. L.; Yang, C. P.; Meng, D.; Pettus, T. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., 3rd; Horwitz, S. B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines Clin. Cancer Res. 2000, 6, 1978-1987
109. Huang, G. S.; Lopez-Barcons, L.; Freeze, B. S.; Smith, A. B., III; Goldberg, G. L.; Horwitz, S. B.; McDaid, H. M. Potentiation of Taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice Clin. Cancer Res. 2006, 12, 298-304
110. Hung, D. T.; Nerenberg, J. B.; Schreiber, S. L. Syntheses of discodermolides useful for investigating microtubule binding and stabilization J. Am. Chem. Soc. 1996, 118, 11054-11080
111. Nerenberg, J. B.; Hung, D. T.; Somers, P. K.; Schreiber, S. L. Total synthesis of the immunosuppressive agent (-)-discodermolide J. Am. Chem. Soc. 1993, 115, 12621-12622
112. Smith, A. B., III; Freeze, B. S. (+)-Discodermolide: total synthesis, construction of novel analogues, and biological evaluation Tetrahedron 2008, 64, 261-298
113. Smith, A. B., 3rd; Kaufman, M. D.; Beauchamp, T. J.; LaMarche, M. J.; Arimoto, H. Gram-scale synthesis of (+)-discodermolide Org. Lett. 1999, 1, 1823-1826
114. Smith, A. B., 3rd; Beauchamp, T. J.; LaMarche, M. J.; Kaufman, M. D.; Qiu, Y.; Arimoto, H.; Jones, D. R.; Kobayashi, K. Evolution of a gram-scale synthesis of (+)-discodermolide J. Am. Chem. Soc. 2000, 122, 8654-8664
115. Paterson, I.; Florence, G. J.; Gerlach, K.; Scott, J. P. Total synthesis of the antimicrotubule agent (+)-discodermolide using boron-mediated aldol reactions of chiral ketones Angew. Chem., Int. Ed. 2000, 39, 377-380
116. Mita, A.; Lockhart, A. C.; Chen, T. L.; Bochinski, K.; Curtright, J.; Cooper, W.; Hammond, L.; Rothenberg, M.; Rowinsky, E.; Sharma, S. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advanced solid malignancies J. Clin. Oncol. 2004, 14S, 2025 (2004 ASCO Annual Meeting Proceedings
117. Paterson, I.; Gardner, N. M. Design, synthesis and biological evaluation of a macrocyclic discodermolide/dictyostatin hybrid Chem. Commun. (Cambridge, U. K.) 2007, 49-51
118. Smith, A. B.; Sugasawa, K.; Atasoylu, O.; Yang, C.-P. H.; Horwitz, S. B. Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity J. Med. Chem. 2011, 54, 6319-6327
119. Burlingame, M. A.; Shaw, S. J.; Sundermann, K. F.; Zhang, D.; Petryka, J.; Mendoza, E.; Liu, F.; Myles, D. C.; LaMarche, M. J.; Hirose, T.; Freeze, S. B.; Smith, A. B., 3rd. Design, synthesis and cytotoxicity of 7-deoxy aryl discodermolide analogues Bioorg. Med. Chem. Lett. 2004, 14, 2335-2338
120. Shaw, S. J.; Sundermann, K. F.; Burlingame, M. A.; Myles, D. C.; Freeze, B. S.; Xian, M.; Brouard, I.; Smith, A. B., 3rd. Toward understanding how the lactone moiety of discodermolide affects activity J. Am. Chem. Soc. 2005, 127, 6532-6533
121. Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Boyd, M. R.; Schmidt, J. M. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1 J. Chem. Soc., Chem. Commun. 1994, 1111-1112
122. Isbrucker, R. A.; Cummins, J.; Pomponi, S. A.; Longley, R. E.; Wright, A. E. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin Biochem. Pharmacol. 2003, 66, 75-82
123. Madiraju, C.; Edler, M. C.; Hamel, E.; Raccor, B. S.; Balachandran, R.; Zhu, G.; Giuliano, K. A.; Vogt, A.; Shin, Y.; Fournier, J. H.; Fukui, Y.; Bruckner, A. M.; Curran, D. P.; Day, B. W. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin Biochemistry 2005, 44, 15053-15063
124. Smith, A. B.; LaMarche, M. J.; Falcone-Hindley, M. Solution structure of (+)-discodermolide Org. Lett. 2001, 3, 695-698
125. Canales, A.; Matesanz, R.; Gardner, N. M.; Andreu, J. M.; Paterson, I.; Díaz, J. F.; Jiménez-Barbero, J. The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin Chem.-Eur. J. 2008, 14, 7557-7569
126. Sánchez-Pedregal, V. M.; Kubicek, K.; Meiler, J.; Lyothier, I.; Paterson, I.; Carlomagno, T. The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide Angew. Chem., Int. Ed. 2006, 45, 7388-7394
127. Paterson, I.; Britton, R.; Delgado, O.; Meyer, A.; Poullennec, K. G. Total synthesis and configurational assignment of (-)-dictyostatin, a microtubule-stabilizing macrolide of marine sponge origin Angew. Chem., Int. Ed. 2004, 43, 4629-4633
128. Shin, Y.; Fournier, J.-H.; Fukui, Y.; Bruckner, A. M.; Curran, D. P. Total synthesis of (-)-dictyostatin: confirmation of relative and absolute configurations Angew. Chem., Int. Ed. 2004, 43, 4634-4637
129. Ramachandran, P. V.; Srivastava, A.; Hazra, D. Total synthesis of potential antitumor agent, (-)-dictyostatin Org. Lett. 2006, 9, 157-160
130. ONei, G. W.; Phillips, A. J. Total synthesis of (-)-dictyostatin J. Am. Chem. Soc. 2006, 128, 5340-5341
131. Paterson, I.; Britton, R.; Delgado, O.; Gardner, N. M.; Meyer, A.; Naylor, G. J.; Poullennec, K. G. Total synthesis of (-)-dictyostatin, a microtubule-stabilising anticancer macrolide of marine sponge origin Tetrahedron 2010, 66, 6534-6545
132. Lindel, T.; Jensen, P. R.; Fenical, W.; Long, B. H.; Casazza, A. M.; Carboni, J.; Fairchild, C. R. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules J. Am. Chem. Soc. 1997, 119, 8744-8745
133. Long, B. H.; Carboni, J. M.; Wasserman, A. J.; Cornell, L. A.; Casazza, A. M.; Jensen, P. R.; Lindel, T.; Fenical, W.; Fairchild, C. R. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol) Cancer Res. 1998, 58, 1111-1115
134. DAmbrosio, M.; Guerriero, A.; Pietra, F. Sarcodictyin A and sarcodictyin B, novel diterpenoidic alcohols esterified by (E)- N (1)-methylurocanic acid. Isolation from the mediterranean stolonifer Sarcodictyon roseum Helv. Chim. Acta 1987, 70, 2019-2027
135. DAnbrosio, M.; Guerriero, A.; Pietra, F. Isolation from the Mediterranean Stolonifern coral Sarcodictyon roseum of sarcodictyin C, D, E, and F, novel diterpenodic alcohols esterified by (E)- or (Z)- N (1)-methylurocanic acid. Failure of the carbon-skeleton type as a classification criterion Helv. Chim. Acta 1988, 71, 964-976 (Abstract 30)
136. Ciomei, M.; Albanese, C.; Pastori, W.; Grandi, M.; Pietra, F.; DAmbrosio, M.; Guerriero, A.; Battistini, C. Sarcodictyins: a new class of marine derivatives with mode of action similar to Taxol Proc. Am. Assoc. Cancer Res 1997, 38, 5
137. Hamel, E.; Sackett, D. L.; Vourloumis, D.; Nicolaou, K. C. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site Biochemistry 1999, 38, 5490-5498
138. McDaid, H. M.; Bhattacharya, S. K.; Chen, X. T.; He, L.; Shen, H. J.; Gutteridge, C. E.; Horwitz, S. B.; Danishefsky, S. J. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines Cancer Chemother. Pharmacol. 1999, 44, 131-137
139. Nicolaou, K. C.; Xu, J. Y.; Kim, S.; Ohshima, T.; Hosokawa, S.; Pfefferkorn, J. Synthesis of the tricyclic core of eleutherobin and sarcodictyins and total synthesis of sarcodictyin A J. Am. Chem. Soc. 1997, 119, 11353-11354
140. Nicolaou, K. C.; van Delft, F.; Ohshima, T.; Vourloumis, D.; Xu, J.; Hosokawa, S.; Pfefferkorn, J.; Kim, S.; Li, T. Total synthesis of eleutherobin Angew. Chem., Int. Ed. Engl. 1997, 36, 2520-2524
141. Nicolaou, K. C.; Ohshima, T.; Hosokawa, S.; van Delft, F. L.; Vourloumis, D.; Xu, J. Y.; Pfefferkorn, J.; Kim, S. Total synthesis of eleutherobin and eleuthosides A and B J. Am. Chem. Soc. 1998, 120, 8674-8680
142. Nicolaou, K. C.; Xu, J. Y.; Kim, S.; Pfefferkorn, J.; Ohshima, T.; Vourloumis, D.; Hosokawa, S. Total synthesis of sarcodictyins A and B J. Am. Chem. Soc. 1998, 120, 8661-8673
143. Chen, X.-T.; Bhattacharya, S. K.; Zhou, B.; Gutteridge, C. E.; Pettus, T. R. R.; Danishefsky, S. J. The total synthesis of eleutherobin J. Am. Chem. Soc. 1999, 121, 6563-6579
144. Chen, X.-T.; Gutteridge, C. E.; Bhattacharya, S. K.; Zhou, B.; Pettus, T. R. R.; Hascall, T.; Danishefsky, S. J. A convergent route for the total synthesis of the eleuthesides Angew. Chem., Int. Ed. 1998, 37, 185-186
145. Chen, X.-T.; Zhou, B.; Bhattacharya, S. K.; Gutteridge, C. E.; Pettus, T. R. R.; Danishefsky, S. J. The total synthesis of eleutherobin: a surprise ending Angew. Chem., Int. Ed. 1998, 37, 789-792
146. Corley, D. G.; Herb, R.; Moore, R. E.; Scheuer, P. J.; Paul, V. J. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator J. Org. Chem. 1988, 53, 3644-3646
147. Quinoa, E.; Kakou, Y.; Crews, P. Fijianolides, polyketide heterocyclics from amarine sponge J. Org. Chem. 1988, 53, 3642-3644
148. Jefford, C. W.; Bernardinelli, G.; Tanaka, J.-i.; Higa, T. Structures and absolute configurations of the marine toxins, latrunculin A and laulimalide Tetrahedron Lett. 1996, 37, 159-162
149. Mooberry, S. L.; Tien, G.; Hernandez, A. H.; Plubrukarn, A.; Davidson, B. S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents Cancer Res. 1999, 59, 653-660
150. Pryor, D. E.; OBrate, A.; Bilcer, G.; Diaz, J. F.; Wang, Y.; Kabaki, M.; Jung, M. K.; Andreu, J. M.; Ghosh, A. K. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity Biochemistry 2002, 41, 9109-9115
151. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2904-2909
152. Hamel, E.; Day, B. W.; Miller, J. H.; Jung, M. K.; Northcote, P. T.; Ghosh, A. K.; Curran, D. P.; Cushman, M.; Nicolaou, K. C.; Paterson, I. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly Mol. Pharmacol. 2006, 70, 1555-1564
153. Bennett, M. J.; Barakat, K.; Huzil, J. T.; Tuszynski, J.; Schriemer, D. C. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping Chem. Biol. 2010, 17, 725-734
154. Ghosh, A. K.; Wang, Y. Total synthesis of (-)-laulimalide J. Am. Chem. Soc. 2000, 122, 11027-11028
155. Mulzer, J.; Ohler, E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity Chem. Rev. 2003, 103, 3753-3786
156. Gallagher, B. M.; Fang, F. G.; Johannes, C. W.; Pesant, M.; Tremblay, M. R.; Zhao, H.; Akasaka, K.; Li, X. Y.; Liu, J.; Littlefield, B. A. Synthesis and biological evaluation of (-)-laulimalide analogues Bioorg. Med. Chem. Lett. 2004, 14, 575-579
157. Liu, J.; Towle, M. J.; Cheng, H.; Saxton, P.; Reardon, C.; Wu, J.; Murphy, E. A.; Kuznetsov, G.; Johannes, C. W.; Tremblay, M. R.; Zhao, H.; Pesant, M.; Fang, F. G.; Vermeulen, M. W.; Gallagher, B. M.; Littlefield, B. A. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent Anticancer Res. 2007, 27, 1509-1518
158. Johnson, T. A.; Tenney, K.; Cichewicz, R. H.; Morinaka, B. I.; White, K. N.; Amagata, T.; Subramanian, B.; Media, J.; Mooberry, S. L.; Valeriote, F. A.; Crews, P. Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties J. Med. Chem. 2007, 50, 3795-3803
159. West, L. M.; Northcote, P. T.; Battershill, C. N. Peloruside A: a potent cytotoxic macrolide isolated from the new zealand marine sponge Mycale sp J. Org. Chem. 2000, 65, 445-449
160. Hood, K. A.; Bäckström, B. T.; West, L. M.; Northcote, P. T.; Berridge, M. V.; Miller, J. H. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C Anti-Cancer Drug Des. 2001, 16, 155-166
161. Gaitanos, T. N.; Buey, R. M.; Diaz, J. F.; Northcote, P. T.; Teesdale-Spittle, P.; Andreu, J. M.; Miller, J. H. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines Cancer Res. 2004, 64, 5063-5067
162. Huzil, J. T.; Chik, J. K.; Slysz, G. W.; Freedman, H.; Tuszynski, J.; Taylor, R. E.; Sackett, D. L.; Schriemer, D. C. A unique mode of microtubule stabilization induced by peloruside A J. Mol. Biol. 2008, 378, 1016-1030
163. Wilmes, A.; OSullivan, D.; Chan, A.; Chandrahasen, C.; Paterson, I.; Northcote, P. T.; La Flamme, A. C.; Miller, J. H. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells Cancer Chemother. Pharmacol. 2011, 68, 117-126
164. Liao, X.; Wu, Y.; De Brabander, J. K. Total synthesis and absolute configuration of the novel microtubule-stabilizing agent peloruside A Angew. Chem., Int. Ed. Engl. 2003, 42, 1648-1652
165. Jin, M.; Taylor, R. E. Total synthesis of (+)-peloruside A Org. Lett. 2005, 7, 1303-1305
166. Ghosh, A. K.; Xu, X.; Kim, J.-H.; Xu, C.-X. Enantioselective total synthesis of peloruside A: a potent microtubule stabilizer Org. Lett. 2008, 10, 1001-1004
167. Evans, D. A.; Welch, D. S.; Speed, A. W.; Moniz, G. A.; Reichelt, A.; Ho, S. An aldol-based synthesis of (+)-peloruside a, a potent microtubule stabilizing agent J. Am. Chem. Soc. 2009, 131, 3840-3841
168. Smith, A. B.; Cox, J. M.; Furuichi, N.; Kenesky, C. S.; Zheng, J.; Atasoylu, O.; Wuest, W. M. Total synthesis of (-)-2-epi-peloruside A Org. Lett. 2008, 10, 5501-5504
169. McGowan, M. A.; Stevenson, C. P.; Schiffler, M. A.; Jacobsen, E. N. An enantioselective total synthesis of (+)-peloruside A Angew. Chem. 2010, 122, 6283-6286
170. Hoye, T. R.; Jeon, J.; Kopel, L. C.; Ryba, T. D.; Tennakoon, M. A.; Wang, Y. Total synthesis of peloruside a through kinetic lactonization and relay ring-closing metathesis cyclization reactions Angew. Chem., Int. Ed. 2010, 49, 6151-6155
171. Dalby, S. M.; Paterson, I. Synthesis of polyketide natural products and analogs as promising anticancer agents Curr. Opin. Drug Discovery Dev. 2010, 13, 777-794
172. Singh, A. J.; Xu, C.-X.; Xu, X.; West, L. M.; Wilmes, A.; Chan, A.; Hamel, E.; Miller, J. H.; Northcote, P. T.; Ghosh, A. K. Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity J. Org. Chem. 2009, 75, 2-10
173. Singh, A. J.; Razzak, M.; Teesdale-Spittle, P.; Gaitanos, T. N.; Wilmes, A.; Paterson, I.; Goodman, J. M.; Miller, J. H.; Northcote, P. T. Structure-activity studies of the pelorusides: new congeners and semi-synthetic analogues Org. Biomol. Chem. 2011, 9, 4456-4466
174. Sato, B.; Muramatsu, H.; Miyauchi, M.; Hori, Y.; Takase, S.; Hino, M.; Hashimoto, S.; Terano, H. A new antimitotic substance, FR182877. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities J. Antibiot. (Tokyo) 2000, 53, 123-130
175. Sato, B.; Nakajima, H.; Hori, Y.; Hino, M.; Hashimoto, S.; Terano, H. A new antimitotic substance, FR182877. II. The mechanism of action J. Antibiot. (Tokyo) 2000, 53, 204-206
176. Yoshimura, S.; Sato, B.; Kinoshita, T.; Takase, S.; Terano, H. A new antimitotic substance, FR182877. III. Structure determination J. Antibiot. (Tokyo) 2000, 53, 615-22
177. (J. Antibiot. 2002, 55, C-1 (errata))
178. Vanderwal, C. D.; Vosburg, D. A.; Weiler, S.; Sorensen, E. J. An enantioselective synthesis of FR182877 provides a chemical rationalization of its structure and affords multigram quantities of its direct precursor J. Am. Chem. Soc. 2003, 125, 5393-5407
179. Vosburg, D. A.; Vanderwal, C. D.; Sorensen, E. J. A synthesis of (+)-FR182877, featuring tandem transannular Diels-Alder reactions inspired by a postulated biogenesis J. Am. Chem. Soc. 2002, 124, 4552-4553
180. Evans, D. A.; Starr, J. T. A cascade cycloaddition strategy leading to the total synthesis of (-)-FR182877 Angew. Chem., Int. Ed. 2002, 41, 1787-1790
181. Edler, M. C.; Buey, R. M.; Gussio, R.; Marcus, A. I.; Vanderwal, C. D.; Sorensen, E. J.; Diaz, J. F.; Giannakakou, P.; Hamel, E. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site Biochemistry 2005, 44, 11525-11538
182. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; Lopez, J. A.; Andreu, J. M.; Hamel, E.; Diaz, J. F. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites Nat. Chem. Biol. 2007, 3, 117-125
183. Prussia, A. J.; Yang, Y.; Geballe, M. T.; Snyder, J. P. Cyclostreptin and microtubules: is a low-affinity binding site required? ChemBioChem 2010, 11, 101-109
184. Field, J. J.; Pera, B.; Calvo, E.; Canales, A.; Zurwerra, D.; Trigili, C.; Rodríguez-Salarichs, J.; Matesanz, R.; Kanakkanthara, A.; Wakefield, S. J.; Singh, A. J.; Jiménez-Barbero, J.; Northcote, P.; Miller, J. H.; López, J. A.; Hamel, E.; Barasoain, I.; Altmann, K.-H.; Díaz, J. F. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules Chem. Biol. 2012, 19, 686-698
185. Scheuer, P.; Swanholm, C.; Madamba, L.; Hudgins, W. The constituents of Tacca leontopetaloides Lloydia 1963, 26, 133-140
186. Chen, Z.; Wang, B.; Chen, M. Steroidal bitter principles from Tacca plantaginea structures of taccalonolide A and B Tetrahedron Lett. 1987, 28, 1673-1675
187. Chen, Z.-L.; Wang, B.-d.; Shen, J.-H. Taccalonolide C and D, two pentacyclic steroids of Tacca plantaginea Phytochemistry 1988, 27, 2999-3001
188. Yang, J. Y.; Zhao, R. H.; Chen, C. X.; Ni, W.; Teng, F.; Hao, X. J.; Liu, H. Y.; Taccalonolides, W.-Y. Three new pentacyclic steroids from Tacca plantaginea Helv. Chim. Acta 2008, 91, 1077-1082
189. Peng, J.; Risinger, A. L.; Fest, G. A.; Jackson, E. M.; Helms, G.; Polin, L. A.; Mooberry, S. L. Identification and biological activities of new taccalonolide microtubule stabilizers J. Med. Chem. 2011, 54, 6117-6124
190. Li, J.; Risinger, A. L.; Peng, J.; Chen, Z.; Hu, L.; Mooberry, S. L. Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers J. Am. Chem. Soc. 2011, 133, 19064-19067
191. Tinley, T. L.; Randall-Hlubek, D. A.; Leal, R. M.; Jackson, E. M.; Cessac, J. W.; Quada, J. C., Jr.; Hemscheidt, T. K.; Mooberry, S. L. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity Cancer Res. 2003, 63, 3211-3220
192. Risinger, A. L.; Jackson, E. M.; Polin, L. A.; Helms, G. L.; LeBoeuf, D. A.; Joe, P. A.; Hopper-Borge, E.; Ludueña, R. F.; Kruh, G. D.; Mooberry, S. L. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms Cancer Res. 2008, 68, 8881-8888
193. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, I.; Mooberry, S.; Andreu, J. M.; DÌaz, J. F. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity Chem. Biol. 2005, 12, 1269-1279
194. Risinger, A. L.; Mooberry, S. L. Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel Cell Cycle 2011, 10, 2162-2171
195. Tanaka, J.-i.; Higa, T. Zampanolide, a new cytotoxic marcrolide from a marine sponge Tetrahedron Lett. 1996, 37, 5535-5538
196. Cutignano, A.; Bruno, I.; Bifulco, G.; Casapullo, A.; Debitus, C.; Gomez-Paloma, L.; Riccio, R. Dactylolide, a new cytotoxic macrolide from the vanuatu sponge Dactylospongia sp Eur. J. Org. Chem. 2001, 2001, 775-778
197. Smith, A. B.; Safonov, I. G.; Corbett, R. M. Total Synthesis of (+)-zampanolide J. Am. Chem. Soc. 2001, 123, 12426-12427
198. Smith, A. B.; Safonov, I. G.; Corbett, R. M. Total syntheses of (+)-zampanolide and (+)-dactylolide exploiting a unified strategy J. Am. Chem. Soc. 2002, 124, 11102-11113
199. Hoye, T. R.; Hu, M. Macrolactonization via Ti(IV)-mediated epoxy-acid coupling: a total synthesis of (-)-dactylolide [and zampanolide] J. Am. Chem. Soc. 2003, 125, 9576-9577
200. Uenishi, J. i.; Iwamoto, T.; Tanaka, J. Total Synthesis of (-)-zampanolide and questionable existence of (-)-dactylolide as the elusive biosynthetic precursor of (-)-zampanolide in an Okinawan sponge Org. Lett. 2009, 11, 3262-3265
201. Ghosh, A. K.; Cheng, X.; Bai, R.; Hamel, E. Total synthesis of potent antitumor macrolide (-)-zampanolide: an oxidative intramolecular cyclization-based strategy Eur. J. Org. Chem. 2012, 4130-4139
202. Smith, A. B.; Safonov, I. G. Total synthesis of (+)-dactylolide Org. Lett. 2002, 4, 635-637
203. Aubele, D. L.; Wan, S.; Floreancig, P. E. Total synthesis of (+)-dactylolide through an efficient sequential peterson olefination and prins cyclization reaction Angew. Chem., Int. Ed. 2005, 44, 3485-3488
204. Sanchez, C. C.; Keck, G. E. Total synthesis of (+)-dactylolide Org. Lett. 2005, 7, 3053-3056
205. Ding, F.; Jennings, M. P. Total synthesis of (-)-dactylolide and formal synthesis of (-)-zampanolide via target oriented β- C -glycoside formation J. Org. Chem. 2008, 73, 5965-5976
206. Louis, I.; Hungerford, N. L.; Humphries, E. J.; McLeod, M. D. Enantioselective total synthesis of (-)-dactylolide Org. Lett. 2006, 8, 1117-1120
207. Field, J. J.; Singh, A. J.; Kanakkanthara, A.; Halafihi, T. i.; Northcote, P. T.; Miller, J. H. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the tongan marine sponge Cacospongia mycofijiensis J. Med. Chem. 2009, 52, 7328-7332
208. Zurwerra, D.; Gertsch, J. r.; Altmann, K.-H. Synthesis of (-)-dactylolide and 13-desmethylene-(-)-dactylolide and their effects on tubulin Org. Lett. 2010, 12, 2302-2305
209. Manzo, E.; van Soest, R.; Matainaho, L.; Roberge, M.; Andersen, R. J. Ceratamines A and B, antimitotic heterocyclic alkaloids isolated from the marine sponge Pseudoceratina sp. collected in Papua New Guinea Org. Lett. 2003, 5, 4591-4594
210. Karjala, G.; Chan, Q.; Manzo, E.; Andersen, R. J.; Roberge, M. Ceratamines, structurally simple microtubule-stabilizing antimitotic agents with unusual cellular effects Cancer Res. 2005, 65, 3040-3043
211. Coleman, R. S.; Campbell, E. L.; Carper, D. J. A direct and efficient total synthesis of the tubulin-binding agents ceratamine A and B; use of IBX for a remarkable heterocycle dehydrogenation Org. Lett. 2009, 11, 2133-2136
212. Nodwell, M.; Zimmerman, C.; Roberge, M.; Andersen, R. J. Synthetic analogues of the microtubule-stabilizing sponge alkaloid ceratamine A are more active than the natural product J. Med. Chem. 2010, 53, 7843-7851
213. Nodwell, M.; Riffell, J. L.; Roberge, M.; Andersen, R. J. Synthesis of antimitotic analogs of the microtubule stabilizing sponge alkaloid ceratamine A Org. Lett. 2008, 10, 1051-1054
214. Madari, H.; Panda, D.; Wilson, L.; Jacobs, R. S. Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol Cancer Res. 2003, 63, 1214-1220
215. Miglietta, A.; Gabriel, L.; Appendino, G.; Bocca, C. Biological properties of jatrophane polyesters, new microtubule-interacting agents Cancer Chemother. Pharmacol. 2003, 51, 67-74
216. Mooberry, S. L.; Stratman, K.; Moore, R. E. Tubercidin stabilizes microtubules against vinblastine-induced depolymerization, a Taxol-like effect Cancer Lett. 1995, 96, 261-266
217. Crabtree, D. V.; Ojima, I.; Geng, X.; Adler, A. J. Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site Bioorg. Med. Chem. 2001, 9, 1967-1976
218. Bassan, M.; Zamostiano, R.; Davidson, A.; Pinhasov, A.; Giladi, E.; Perl, O.; Bassan, H.; Blat, C.; Gibney, G.; Glazner, G.; Brenneman, D. E.; Gozes, I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide J. Neurochem. 1999, 72, 1283-1293
219. Gozes, I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide) Curr. Pharm. Des. 2011, 17, 3413-3417
220. Gozes, I.; Morimoto, B. H.; Tiong, J.; Fox, A.; Sutherland, K.; Dangoor, D.; Holser-Cochav, M.; Vered, K.; Newton, P.; Aisen, P. S. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) CNS Drug Rev. 2005, 11, 353-368
221. Gozes, I. Davunetide (AL-108): targeting tangles Alzheimer's Dementia 2009, 5, P74-P74
222. Divinski, I.; Mittelman, L.; Gozes, I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication J. Biol. Chem. 2004, 279, 28531-28538
223. Divinski, I.; Holtser-Cochav, M.; Vulih-Schultzman, I.; Steingart, R. A.; Gozes, I. Peptide neuroprotection through specific interaction with brain tubulin J. Neurochem. 2006, 98, 973-984
224. Yenjerla, M.; LaPointe, N. E.; Lopus, M.; Cox, C.; Jordan, M. A.; Feinstein, S. C.; Wilson, L. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules J. Alzheimer's Dis. 2010, 19, 1377-1386
225. Shintani, Y.; Tanaka, T.; Nozaki, Y. GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol Cancer Chemother. Pharmacol. 1997, 40, 513-520
226. Wang, Z.; Yang, D.; Mohanakrishnan, A. K.; Fanwick, P. E.; Nampoothiri, P.; Hamel, E.; Cushman, M. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability J. Med. Chem. 2000, 43, 2419-2429
227. Li, P. K.; Pandit, B.; Sackett, D. L.; Hu, Z.; Zink, J.; Zhi, J.; Freeman, D.; Robey, R. W.; Werbovetz, K.; Lewis, A.; Li, C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule- stabilizing activities Mol. Cancer Ther. 2006, 5, 450-456
228. Zhang, N.; Ayral-Kaloustian, S.; Nguyen, T.; Afragola, J.; Hernandez, R.; Lucas, J.; Gibbons, J.; Beyer, C. Synthesis and SAR of [1,2,4]triazolo[1,5- a ]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition J. Med. Chem. 2007, 50, 319-327
229. Zhang, N.; Ayral-Kaloustian, S.; Nguyen, T.; Hernandez, R.; Lucas, J.; Discafani, C.; Beyer, C. Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2- heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents Bioorg. Med. Chem. 2009, 17, 111-118
230. Crowley, P. J.; Lamberth, C.; Müller, U.; Wendeborn, S.; Nebel, K.; Williams, J.; Sageot, O.-A.; Carter, N.; Mathie, T.; Kempf, H.-J.; Godwin, J.; Schneiter, P.; Dobler, M. R. Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 1: pyrido[2,3- b ]pyrazines Pest Manage. Sci. 2010, 66, 178-185
231. Crowley, P. J.; Lamberth, C.; Müller, U.; Wendeborn, S.; Sageot, O.-A.; Williams, J.; Bartovič, A. Niementowski-type synthesis of pyrido[3,2- e ][1,2,4]triazines: potent aza -analogs of pyrido[2,3- b ]pyrazine fungicides Tetrahedron Lett. 2010, 51, 2652-2654
232. Lamberth, C.; Trah, S.; Wendeborn, S.; Dumeunier, R.; Courbot, M.; Godwin, J.; Schneiter, P. Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 2: Pyridazines Bioorg. Med. Chem. 2012, 20, 2803-2810
233. Beyer, C. F.; Zhang, N.; Hernandez, R.; Vitale, D.; Lucas, J.; Nguyen, T.; Discafani, C.; Ayral-Kaloustian, S.; Gibbons, J. J. TTI-237: a novel microtubule-active compound with in vivo antitumor activity Cancer Res. 2008, 68, 2292-300
234. Beyer, C. F.; Zhang, N.; Hernandez, R.; Vitale, D.; Nguyen, T.; Ayral-Kaloustian, S.; Gibbons, J. J. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties Cancer Chemother. Pharmacol. 2009, 64, 681-689
235. Ayral-Kaloustian, S.; Zhang, N.; Beyer, C. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent Methods Find. Exp. Clin. Pharmacol. 2009, 31, 443-447
236. Lee, V. M.-Y.; Brunden, K. R.; Hutton, M.; Trojanowski, J. Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets Cold Spring Harbor Perspect. Med. 2011, 1, a006437
237. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y. Advances in tau-focused drug discovery for Alzheimers disease and related tauopathies Nat. Rev. Drug Discovery 2009, 8, 783-793